BRL Medicine

Executive Summary

BRL Medicine is a Beijing-based biotechnology company at the forefront of next-generation cell therapies, focusing on CAR-T and TCR-T platforms for both hematological and solid tumors. Founded in 2016, the company leverages proprietary gene editing and cell engineering technologies to enhance the persistence and efficacy of its therapies while mitigating toxicity. With over 200 employees, BRL Medicine has advanced multiple programs into clinical and preclinical stages, positioning itself as a key player in China's competitive cell therapy landscape. Its lead CAR-T candidate targets CD19-positive hematologic malignancies and is currently in Phase 2 trials, while its TCR-T pipeline addresses solid tumors such as liver and gastric cancers, representing a significant growth opportunity. Recent progress includes the completion of dose-escalation cohorts for its lead CAR-T program, with preliminary data suggesting a favorable safety profile and encouraging response rates. The company is also advancing preclinical studies for its allogeneic CAR-T platform and a novel TCR-T candidate targeting neoantigens. As of April 2026, BRL Medicine is well-funded and actively pursuing regulatory milestones. The global cell therapy market is projected to exceed $10 billion by 2028, and BRL Medicine's differentiated technology and broad pipeline could capture substantial share, particularly in Asia. With multiple catalysts on the horizon and a strong intellectual property portfolio, the company represents a compelling investment opportunity in the oncology space.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead CAR-T program in hematologic malignancies65% success
• Q2 2026Initiation of Phase 1 trial for TCR-T candidate in solid tumors80% success
• Q4 2026Potential partnership or licensing deal for gene editing platform55% success